HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

AuthorsCatherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, Bruce Sill, Shalini Hede, Yong Yuan, Boris Gorsh
JournalJournal of medical economics (J Med Econ) Vol. 20 Issue 11 Pg. 1123-1125 (Nov 2017) ISSN: 1941-837X [Electronic] England
PMID28745536 (Publication Type: Journal Article)
Chemical References
  • Carbamates
  • Imidazoles
  • Pyrrolidines
  • Valine
  • daclatasvir
  • Sofosbuvir
Topics
  • Carbamates
  • Cost-Benefit Analysis
  • Genotype
  • Hepatitis C, Chronic
  • Humans
  • Imidazoles
  • Pyrrolidines
  • Sofosbuvir
  • United States
  • Valine (analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: